

# Monash Absolute Investment Company Limited (ASX: MA1) April 2018 End of Month Update

7 May 2018

In the interests of keeping the market fully informed of performance on a timely basis, we release a preliminary estimate of the Pre-Tax Net Tangible Asset Backing per share. It is only a guide, the official NTA will be released later in the month.

We estimate that as at 30 April 2018 the NTA Pre-Tax was \$0.9337.

### **Company Strategy**

The Company is benchmark unaware, style and stock size agnostic, both long and short, and only invests in compelling opportunities. In keeping with the Company's absolute return objectives, if the investment manager cannot find stocks that meet the very high return hurdle requirements, the Company will preserve that capital in cash at bank.

In December 2017, the Company announced a renewal of the on-market buy-back as part of its ongoing capital management program. During the month of April, 397,504 shares were bought under the Company's on market share buyback.

#### **Monthly Commentary**

The Company's pre-tax NTA decreased 4.88% (after fees) for the month of April, during which the S&P/ASX200 rose 3.91% and the Small Ords rose 2.75%.

In April there was a lot of news flow for stocks in the portfolio, in contrast to March, which was quiet. And unlike March, where the portfolio beat the market indices, in April the portfolio went the other way.

While the number of positive news announcements for stocks in the portfolio was equal in number to the negative announcements, the negative surprises had a greater effect on the stock share prices. Despite the disappointing result this month, the NTA is up 6.79% after fees this financial year.

In this month's update we will review both the good, the bad, and the mixed.

### Company at a Glance 30 April 2018

ASX Code	MA1	
Portfolio Size	\$46.3m	
Share Price	\$0.815	
Shares on Issue	49.4m	

### Estimated NTA (unaudited) 30 April 2018

Estimated NTA Pre Tax		\$0.9337

#### **Return Estimate to 30 April 2018**

	NTA Pre Tax
1 Month	-4.88%
3 Months	-8.41%
6 Months	-3.35%
FYTD	6.79%
1 Year	7.84%
Since Inception p.a.	-1.50%

### Portfolio Structure 30 April 2018

Outlook Stocks (Long)	15 Positions	59%
Outlook Stocks (Short)	2 Positions	-5%
Event, Pair and Group (Long)	3 Positions	15%
Event, Pair and Group (Short)	1 Positions	-1%
Cash		32%
TOTAL		100%
Gross Exposure		81%
Net Exposure		68%

For more information about the Company and the strategy, please refer to the Monash Investors website at <a href="www.monashinvestors.com">www.monashinvestors.com</a>. You can also <a href="follow us on Livewire here">follow us on Livewire here</a> or subscribe to our updates here





### The Good

**Netcomm Wireless** (ASX: NTC) +16%: Netcomm surprised the market by signing a product purchase agreement with Bell Canada for the supply Fixed Wireless broadband devices, similar to the Netcomm units that NBN and AT&T are rolling out to urban fringe and rural customers. This is only the third such contract of its type in the world; Netcomm invented the product and is the only successful tenderer so far.

**Leigh Creek** (ASX: LCK) +100%: While this is a big jump in the share price it is only a small holding for the portfolio, given the event driven nature of our investment and the size of the company. LCK is developing a coal gasification project in South Australia, and received environmental approval mid-April. The next catalyst for the stock price will be successful flaring, after which the resource should be upgraded from contingent to proven. It amounts to around 4% of Australia's gas reserves.

**NextDC** (ASX: NXT) +5%: During the month NXT undertook a capital raising to fund the purchase of land for the next generation of data centres. What surprised us and the market was the scale of these new centres. NXT total available capacity was 129 megawatts (MW) and this has been increased to 306MW. The original S1 facility was 16MW, the under construction S2 is 40MW, and the newly announced S3 will be 80MW. While it will be some time before this new capacity is required, it clearly demonstrates management's confidence in the outlook for the business.

**MicroX** (ASX:MX1) +3%: MicroX signed a contract with the UK Ministry of Defence to undertake the first phase of Research and Development into a lightweight x-ray imaging system for detecting explosives hidden in consumer electronic devices. This is part of a program with the Department of Transport to improve aviation safety.

### The Bad

**Experience Co** (ASX: EXP) -18%: EXP downgraded its FY18 EBITDA guidance by 15% due to unseasonably bad weather during the March and April peak periods in North Queensland for key operations. In the past, EXP's business has bounced back promptly from rain interruptions and we see no reason why it will not do so again. The business continues to grow strongly notwithstanding this setback, and the EPS will be up 13% in FY18.

**AirXpanders** (ASX: AXP) -54% based on our average exit price: In a shock announcement AXP disclosed flat sales in 3Q vs 2Q. Prior to this, all company announcements stated growing adoption as measured by the signing on of new hospitals and the growing usage per month on average by each surgeon. It was such a shock to the AXP Board that they immediately sacked the CEO. We immediately exited the stock, as it was a violation of the investment thesis. The stock fell another 26% after we exited.

**G8 Education** (ASX: GEM) -14%: At its AGM management noted that continuing tough industry conditions (both supply and demand) had reduced their occupancy rates by 2.5-3% so far this year compared to the February estimate of 1-1.5%. This led to high single digit earnings downgrades by analysts. However, industry conditions will improve significantly following the implementation of the new government childcare subsidy on 1 July and will improve GEM outlook. At the time of writing, the stock has bounced back 7.5%.





#### The Mixed

**Impedimed** (ASX: IPD) -25%: The positive news for Impedimed in April was the long awaited interim results of its Lymphedema trial, which showed a 67% improvement in outcomes using its product, versus the traditional approach. There is still a number of years for the trial to continue. However, it is on track to show a large and statistically significant benefit that will lead to its widespread adoption. The negative news for Impedimed was its quarterly report that showed in the absence of this adoption its sales continue to be slow and it is burning cash. There is a great deal of upside in this stock contingent on the roll out to come, so we continue to hold it at a modest weight.

Lovisa (ASX: LOV) -2%: The positive news for Lovisa was that like for like sales growth to the end of Q3 FY 2018 was 7.6%, which is very strong, and has been achieved at a time when they have been reporting strong margins. Due to the addition of new stores that they have been rolling out in the UK, France, Spain and the USA, we estimate that they will do about a 20% increase in sales overall this year. The negative news was the resignation of the CEO who has been in that position for only 1.5 years, and a total of 2.5 years at the company "to pursue other interests". However, founder and MD, Shane Fallscheer (previously CEO), will continue to lead the company and step back into the CEO role (at least for the time being). We have maintained our weight in this stock.

**Alexium** (ASX: AJX) -41%: The positive news for Alexium was that (i) analytical testing showed pillows treated with Alexicool deliver over 500% greater cooling capacity compared to other commercially available pillows. This means manufacturers can buy far less Alexicool in order to achieve the same effect than other products, making Alexicool much more cost effective than alternatives. In addition (ii) they are making excellent progress in three of their verticals, and success in any of these should result in material sales growth this calendar year. The negative was the disclosure in a letter to shareholders that in the March quarter that they were prompted to develop this new industry accepted test for cooling because, in the absence of this evidence, there had been pricing pressure on their cooling chemicals currently supplied to the bedding industry for mattresses. We continue to hold a modest weight in this stock.

## For all business development enquiries, please contact Winston Capital Partners (Acting on behalf of Monash Investors)

Andrew Fairweather	P: +61 401 716 043	
	Andrew&winstoncapital.com.au	
Rory Macintyre	P: +61 434 669 524	
	rory@winstoncapital.com.au	
Stephen Robertson	P: +61 418 387 427	
	stephen@winstoncapital.com.au	

#### For shareholder enquiries, please contact

Boardroom Pty Limited P: 1300 737 760 (in Australia) +612 9290 9600 (international)

E: enquiries@boardroomlimited.com.au





This presentation has been prepared by Monash Absolute Investment Company Limited (MA1) and Monash Investors Pty Ltd (ABN 67 153 180 333, AFSL 417 201) (Investment Manager) as authorised representatives of Winston Capital Partners Pty Ltd ABN 29 159 382 813, AFSL 469 556 ("Winston Capital") for the provision of general financial product advice in relation to MA1 and is for information purposes only, and does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any securities in MA1. The information is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this information, MA1 has not considered the objectives, financial position or needs of any particular recipient. MA1 strongly suggests that investors consult a financial advisor prior to making an investment decision. Past performance is not a reliable indicator of future performance. See the ASX Company Announcements platform at www.asx.com.au for further information.